Biogen Valuation
| BIIB Stock | USD 143.00 0.74 0.52% |
At this time, the firm appears to be overvalued. Biogen Inc shows a prevailing Real Value of $120.23 per share. The current price of the firm is $143.0. Our model approximates the value of Biogen Inc from analyzing the firm fundamentals such as Current Valuation of 26.6 B, profit margin of 0.15 %, and Return On Equity of 0.0913 as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Biogen's price fluctuation is very steady at this time. Calculation of the real value of Biogen Inc is based on 3 months time horizon. Increasing Biogen's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Biogen is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Biogen Stock. However, Biogen's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 143.0 | Real 120.23 | Hype 143.0 | Naive 136.4 |
The real value of Biogen Stock, also known as its intrinsic value, is the underlying worth of Biogen Inc Company, which is reflected in its stock price. It is based on Biogen's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Biogen's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Biogen Inc helps investors to forecast how Biogen stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Biogen more accurately as focusing exclusively on Biogen's fundamentals will not take into account other important factors: Biogen Total Value Analysis
Biogen Inc is currently forecasted to have valuation of 26.6 B with market capitalization of 20.97 B, debt of 6.63 B, and cash on hands of 4.91 B. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Biogen fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
26.6 B | 20.97 B | 6.63 B | 4.91 B |
Biogen Investor Information
About 93.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.29. Some equities with similar Price to Book (P/B) outperform the market in the long run. Biogen Inc recorded earning per share (EPS) of 10.45. The entity had not issued any dividends in recent years. The firm had 3:1 split on the 18th of January 2001. Based on the analysis of Biogen's profitability, liquidity, and operating efficiency, Biogen Inc is not in a good financial situation at the moment. It has a very high risk of going through financial straits in November.Biogen Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Biogen has an asset utilization ratio of 34.5 percent. This suggests that the Company is making $0.34 for each dollar of assets. An increasing asset utilization means that Biogen Inc is more efficient with each dollar of assets it utilizes for everyday operations.Biogen Ownership Allocation
Biogen holds a total of 146.61 Million outstanding shares. The majority of Biogen Inc outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Biogen Inc to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Biogen. Please pay attention to any change in the institutional holdings of Biogen Inc as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Biogen Profitability Analysis
The company reported the previous year's revenue of 9.68 B. Net Income was 1.63 B with profit before overhead, payroll, taxes, and interest of 7.63 B.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Biogen's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Biogen and how it compares across the competition.
About Biogen Valuation
The stock valuation mechanism determines Biogen's current worth on a weekly basis. Our valuation model uses a comparative analysis of Biogen. We calculate exposure to Biogen's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Biogen's related companies.Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts. Biogen operates under Drug ManufacturersGeneral classification in the United States and is traded on NASDAQ Exchange. It employs 9610 people.
Biogen Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 145.9 M | |
| Quarterly Earnings Growth Y O Y | 0.083 | |
| Forward Price Earnings | 9.6899 |
Complementary Tools for Biogen Stock analysis
When running Biogen's price analysis, check to measure Biogen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biogen is operating at the current time. Most of Biogen's value examination focuses on studying past and present price action to predict the probability of Biogen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biogen's price. Additionally, you may evaluate how the addition of Biogen to your portfolios can decrease your overall portfolio volatility.
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets |